Stanford
University
  • Stanford Home
  • Maps & Directions
  • Search Stanford
  • Emergency Info
  • Terms of Use
  • Privacy
  • Copyright
  • Trademarks
  • Non-Discrimination
  • Accessibility
© Stanford University.  Stanford, California 94305.
Response to FTC's Advanced Notice of Proposed Rulemaking on Commercial Surveillance and Data Security | Stanford HAI

Stay Up To Date

Get the latest news, advances in research, policy work, and education program updates from HAI in your inbox weekly.

Sign Up For Latest News

Navigate
  • About
  • Events
  • Careers
  • Search
Participate
  • Get Involved
  • Support HAI
  • Contact Us
Skip to content
  • About

    • About
    • People
    • Get Involved with HAI
    • Support HAI
    • Subscribe to Email
  • Research

    • Research
    • Fellowship Programs
    • Grants
    • Student Affinity Groups
    • Centers & Labs
    • Research Publications
    • Research Partners
  • Education

    • Education
    • Executive and Professional Education
    • Government and Policymakers
    • K-12
    • Stanford Students
  • Policy

    • Policy
    • Policy Publications
    • Policymaker Education
    • Student Opportunities
  • AI Index

    • AI Index
    • AI Index Report
    • Global Vibrancy Tool
    • People
  • News
  • Events
  • Industry
  • Centers & Labs
policyResponse to Request

Response to FTC's Advanced Notice of Proposed Rulemaking on Commercial Surveillance and Data Security

Date
November 21, 2022
Topics
Privacy, Safety, Security
Regulation, Policy, Governance
Read Paper
abstract

Stanford scholars respond to a federal RFC on commercial surveillance and data security, focusing on the intersection of automated decision-making and information privacy.

Executive Summary

In this response to the Federal Trade Commission’s (FTC) advance notice on proposed rulemaking on commercial surveillance and data security, Stanford HAI scholars challenge the assumption that data minimization and purpose limitation principles are inherently barriers to innovation. They argue that companies must be held to high standards when building automated decision-making systems based on personal data and call for a shift away from the current data acquisition landscape, where companies are the primary stewards of consumers’ personal data. Instead, they advocate for data intermediaries and investment in public data infrastructure for automated decision-making that is more resilient and less dependent on private actors.

Read Paper
Share
Link copied to clipboard!
Authors
  • Jennifer King
    Jennifer King
  • headshot
    Caroline Meinhardt
  • Abel Ribbink
    Abel Ribbink
  • Pete Warden
    Pete Warden
  • Daniel Zhang
    Daniel Zhang
  • James Zou
    James Zou

Related Publications

Response to OSTP's Request for Information on Accelerating the American Scientific Enterprise
Rishi Bommasani, John Etchemendy, Surya Ganguli, Daniel E. Ho, Guido Imbens, James Landay, Fei-Fei Li, Russell Wald
Quick ReadDec 26, 2025
Response to Request

Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.

Response to Request

Response to OSTP's Request for Information on Accelerating the American Scientific Enterprise

Rishi Bommasani, John Etchemendy, Surya Ganguli, Daniel E. Ho, Guido Imbens, James Landay, Fei-Fei Li, Russell Wald
Sciences (Social, Health, Biological, Physical)Regulation, Policy, GovernanceQuick ReadDec 26

Stanford scholars respond to a federal RFI on scientific discovery, calling for the government to support a new “team science” academic research model for AI-enabled discovery.

Response to FDA's Request for Comment on AI-Enabled Medical Devices
Desmond C. Ong, Jared Moore, Nicole Martinez-Martin, Caroline Meinhardt, Eric Lin, William Agnew
Quick ReadDec 02, 2025
Response to Request

Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.

Response to Request

Response to FDA's Request for Comment on AI-Enabled Medical Devices

Desmond C. Ong, Jared Moore, Nicole Martinez-Martin, Caroline Meinhardt, Eric Lin, William Agnew
HealthcareRegulation, Policy, GovernanceQuick ReadDec 02

Stanford scholars respond to a federal RFC on evaluating AI-enabled medical devices, recommending policy interventions to help mitigate the harms of AI-powered chatbots used as therapists.

Jen King's Testimony Before the U.S. House Committee on Energy and Commerce Oversight and Investigations Subcommittee
Jennifer King
Quick ReadNov 18, 2025
Testimony

In this testimony presented to the U.S. House Committee on Energy and Commerce’s Subcommittee on Oversights and Investigations hearing titled “Innovation with Integrity: Examining the Risks and Benefits of AI Chatbots,” Jen King shares insights on data privacy concerns connected with the use of chatbots. She highlights opportunities for congressional action to protect chatbot users from related harms.

Testimony

Jen King's Testimony Before the U.S. House Committee on Energy and Commerce Oversight and Investigations Subcommittee

Jennifer King
Privacy, Safety, SecurityQuick ReadNov 18

In this testimony presented to the U.S. House Committee on Energy and Commerce’s Subcommittee on Oversights and Investigations hearing titled “Innovation with Integrity: Examining the Risks and Benefits of AI Chatbots,” Jen King shares insights on data privacy concerns connected with the use of chatbots. She highlights opportunities for congressional action to protect chatbot users from related harms.

Russ Altman’s Testimony Before the U.S. Senate Committee on Health, Education, Labor, and Pensions
Russ Altman
Quick ReadOct 09, 2025
Testimony

In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.

Testimony

Russ Altman’s Testimony Before the U.S. Senate Committee on Health, Education, Labor, and Pensions

Russ Altman
HealthcareRegulation, Policy, GovernanceSciences (Social, Health, Biological, Physical)Quick ReadOct 09

In this testimony presented to the U.S. Senate Committee on Health, Education, Labor, and Pensions hearing titled “AI’s Potential to Support Patients, Workers, Children, and Families,” Russ Altman highlights opportunities for congressional support to make AI applications for patient care and drug discovery stronger, safer, and human-centered.